Close Menu

Proteome Sciences said this week that it has signed an agreement with Thermo Fisher Scientific providing access to patents related to its Tandem Mass Tags isobaric tagging reagents in exchange for cash and a no-cost lease from Thermo Fisher for mass spectrometry equipment.

The company plans to use that equipment to further develop its SysQuant assays for measuring activation of cancer signaling pathways with the ultimate goal of building clinical test for guiding personalized cancer treatment, Proteome Sciences COO Ian Pike, told ProteoMonitor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.